Jaguar Health (JAGX) announced that the company plans to pursue approval from the European Medicines Agency’s Committee for Veterinary Medicinal Products for Canalevia in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration as a prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar plans to submit a dossier to the European Medicines Agency’s Committee for Veterinary Medical Products to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Extends Maturity Date for Notes
- Jaguar Health provides update on orphan disease intestinal failure program
- Jaguar Health files to sell 507.4K shares of common stock for holders
- Jaguar Health establishes first study site for Canalevia-CA1 field study
- Jaguar Health provides update on Type C meeting with FDA